ArticleVaccine2008
Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.Human vaccines & immunotherapeutics · 2024Review
- E6020, a TLR4 Agonist Adjuvant, Enhances Both Antibody Titers and Isotype Switching in Response to Immunization with Hapten-Protein Antigens and Is Diminished in Mice with TLR4 Signaling Insufficiency.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4Journal for immunotherapy of cancer · 2022Review
- Macroglobulinemia and Autoinflammatory Disease.Rheumatology and immunology research · 2021Review
- Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and AntioxidantInternational journal of molecular sciences · 2021Article
- Nanoparticle or conventional adjuvants: which one improves immune response against Brucellosis?Iranian journal of basic medical sciences · 2019Article
- Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure.The Journal of general virology · 2016Review
- Recent progress in adjuvant discovery for peptide-based subunit vaccines.Human vaccines & immunotherapeutics · 2014Review
- Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.DNA and cell biology · 2012Article
- NOD1 and NOD2 Signaling in Infection and Inflammation.Frontiers in immunology · 2012Article
- Dectin-1 and NOD2 mediate cathepsin activation in zymosan-induced arthritis in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011Article
- The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes.Immunity · 2011Article
- The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation.Trends in immunology · 2011Article
- NLR functions beyond pathogen recognition.Nature immunology · 2011Article
- Vaccine adjuvants: putting innate immunity to work.Immunity · 2010Review
- Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination.Cancer science · 2010Article
- T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii.Nature immunology · 2009Article
- Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.Pediatric research · 2009Review
- Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis.Journal of leukocyte biology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The mechanisms underlying adjuvant effects are under renewed scrutiny because of the enormous implications for vaccine development. Additionally, new low-toxicity adjuvants are sought to enhance vaccine formulations. Muramyl dipeptide (MDP) is a component of the peptidoglycan polymer and was shown to be an active but low-toxicity component of complete Freund's adjuvant, a powerful adjuvant composed of mycobacteria lysates in an oil emulsion. MDP activates cells primarily via the cytosolic NLR family member Nod2 and is therefore linked to the ability of adjuvants to enhance antibody production. Accordingly, we tested the adjuvant properties of the MDP-Nod2 pathway. We found that MDP, compared to the TLR agonist lipopolysaccharide, has minimal adjuvant properties for antibody production under a variety of immunization conditions. We also observed that the oil emulsion incomplete Freund's adjuvant (IFA) supplanted the requirements for the TLR pathway independent of the antigen. Surprisingly, we observed that Nod2 was required for an optimal IgG1 and IgG2c response in the absence of exogenous TLR or NLR agonists. Collectively, our results argue that oil emulsions deserve greater attention for their immunostimulatory properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.